Philippines OTC Pharmaceutical Market Size, Share, Report: By Product Type: Pain Relievers, Anti-allergic, Gastrointestinal Drugs, Vitamins and Minerals, Cough and Cold Remedies, Others; By Distribution Channel: Retail Pharmacies, Online Pharmacies, Drug Stores; By Formulation Type: Tablets, Others; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Philippines OTC Pharmaceutical Market Overview 
    3.1    Philippines OTC Pharmaceutical Market Historical Value (2017-2023) 
    3.2    Philippines OTC Pharmaceutical Market Forecast Value (2024-2032)
4    Philippines OTC Pharmaceutical Market Dynamics
    4.1    Market Drivers and Constraints
    4.2    SWOT Analysis
        4.2.1    Strengths
        4.2.2    Weaknesses
        4.2.3    Opportunities
        4.2.4    Threats
    4.3    Porter’s Five Forces Model
        4.3.1    Bargaining Power of Suppliers
        4.3.2    Bargaining Power of Buyers
        4.3.3    Threat of New Entrants
        4.3.4    Threat of Substitutes
        4.3.5    Degree of Rivalry 
    4.4    Key Demand Indicators
    4.5    Key Price Indicators
    4.6    Industry Events, Initiatives, and Trends 
    4.7    Value Chain Analysis
5    Philippines OTC Pharmaceutical Market Segmentation 
    5.1    Philippines OTC Pharmaceutical Market by Product Type
        5.1.1    Market Overview                                          
        5.1.2    Pain Relievers
        5.1.3    Anti-allergic
        5.1.4    Gastrointestinal Drugs
        5.1.5    Vitamins and Minerals
        5.1.6    Cough and Cold Remedies
        5.1.7    Others
    5.2    Philippines OTC Pharmaceutical Market by Distribution Channel
        5.2.1    Retail Pharmacies
        5.2.2    Online Pharmacies
        5.2.3    Drug Stores
    5.3    Philippines OTC Pharmaceutical Market by Formulation Type
        5.3.1    Market Overview
        5.3.2    Tablets
        5.3.3    Liquids
        5.3.4    Ointments
        5.3.5    Sprays
6    Patent Analysis
    6.1    Analysis by Type of Patent
    6.2    Analysis by Publication Year
    6.3    Analysis by Issuing Authority
    6.4    Analysis by Patent Age
    6.5    Analysis by CPC Analysis
    6.6    Analysis by Patent Valuation 
    6.7    Analysis by Key Players
7    Grants Analysis
    7.1    Analysis by Year
    7.2    Analysis by Amount Awarded
    7.3    Analysis by Issuing Authority
    7.4    Analysis by Grant Application
    7.5    Analysis by Funding Institute
    7.6    Analysis by NIH Departments
    7.7    Analysis by Recipient Organization 
8    Funding Analysis
    8.1    Analysis by Funding Instances
    8.2    Analysis by Type of Funding
    8.3    Analysis by Funding Amount
    8.4    Analysis by Leading Players
    8.5    Analysis by Leading Investors
    8.6    Analysis by Geography
9    Partnership and Collaboration Analysis
    9.1    Analysis by Partnership Instances
    9.2    Analysis by Type of Partnership
    9.3    Analysis by Leading Players
    9.4    Analysis by Geography
10    Regulatory Framework
    10.1    Regulatory Overview
11    Supplier Landscape
    11.1    Johnson & Johnson
        11.1.1    Financial Analysis
        11.1.2    Product Portfolio
        11.1.3    Demographic Reach and Achievements
        11.1.4    Mergers and Acquisitions
        11.1.5    Certifications
    11.2    GlaxoSmithKline
        11.2.1    Financial Analysis
        11.2.2    Product Portfolio
        11.2.3    Demographic Reach and Achievements
        11.2.4    Mergers and Acquisitions
        11.2.5    Certifications
    11.3    Bayer AG
        11.3.1    Financial Analysis
        11.3.2    Product Portfolio
        11.3.3    Demographic Reach and Achievements
        11.3.4    Mergers and Acquisitions
        11.3.5    Certifications
    11.4    Pfizer Inc.
        11.4.1    Financial Analysis
        11.4.2    Financial Portfolio
        11.4.3    Demographic Reach and Achievements
        11.4.4    Mergers and Acquisitions
        11.4.5    Certifications
    11.5    Sanofi
        11.5.1    Financial Analysis
        11.5.2    Product Portfolio
        11.5.3    Demographic Reach and Achievements
        11.5.4    Mergers and Acquisitions
        11.5.5    Certifications
    11.6    Novartis International AG
        11.6.1    Financial Analysis
        11.6.2    Product Portfolio
        11.6.3    Demographic Reach and Achievements
        11.6.4    Mergers and Acquisitions
        11.6.5    Certifications
    11.7    Procter & Gamble
        11.7.1    Financial Analysis
        11.7.2    Product Portfolio
        11.7.3    Demographic Reach and Achievements
        11.7.4    Mergers and Acquisitions
        11.7.5    Certifications
    11.8    Reckitt Benckiser Group plc
        11.8.1    Financial Analysis
        11.8.2    Product Portfolio
        11.8.3    Demographic Reach and Achievements
        11.8.4    Mergers and Acquisitions
        11.8.5    Certifications
    11.9    Takeda Pharmaceutical Company Limited
        11.9.1    Financial Analysis
        11.9.2    Product Portfolio
        11.9.3    Demographic Reach and Achievements
        11.9.4    Mergers and Acquisitions
        11.9.5    Certifications
    11.10    Boehringer Ingelheim
        11.10.1    Financial Analysis
        11.10.2    Product Portfolio
        11.10.3    Demographic Reach and Achievements
        11.10.4    Mergers and Acquisitions
        11.10.5    Certifications
    11.11    Sun Pharmaceutical Industries Ltd.
        11.11.1    Financial Analysis
        11.11.2    Product Portfolio
        11.11.3    Demographic Reach and Achievements
        11.11.4    Mergers and Acquisitions
        11.11.5    Certifications
    11.12    Perrigo Company plc
        11.12.1    Financial Analysis
        11.12.2    Product Portfolio
        11.12.3    Demographic Reach and Achievements
        11.12.4    Mergers and Acquisitions
        11.12.5    Certifications
    11.13    Teva Pharmaceutical Industries Ltd.
        11.13.1    Financial Analysis
        11.13.2    Product Portfolio
        11.13.3    Demographic Reach and Achievements
        11.13.4    Mergers and Acquisitions
        11.13.5    Certifications
    11.14    Mylan N.V. (now part of Viatris Inc.)
        11.14.1    Financial Analysis
        11.14.2    Product Portfolio
        11.14.3    Demographic Reach and Achievements
        11.14.4    Mergers and Acquisitions
        11.14.5    Certifications
    11.15    Cipla Limited
        11.15.1    Financial Analysis
        11.15.2    Product Portfolio
        11.15.3    Demographic Reach and Achievements
        11.15.4    Mergers and Acquisitions
        11.15.5    Certifications
12    Philippines OTC Pharmaceutical Market - Distribution Model (Additional Insight) 
    12.1    Overview 
    12.2    Potential Distributors 
    12.3    Key Parameters for Distribution Partner Assessment 
13    Key Opinion Leaders (KOL) Insights (Additional Insight)
14    Company Competitiveness Analysis (Additional Insight)
    14.1    Very Small Companies
    14.2    Small Companies
    14.3    Mid-Sized Companies
    14.4    Large Companies
    14.5    Very Large Companies
15    Payment Methods (Additional Insight) 
    15.1    Government Funded
    15.2    Private Insurance
    15.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.